- Home
- ACRV vs DTIL Comparison
ACRV vs DTIL Comparison
Compare ACRV & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- DTIL
- Stock Information
- Founded
- ACRV 2018
- DTIL 2006
- Country
- ACRV United States
- DTIL United States
- Employees
- ACRV N/A
- DTIL N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- ACRV Health Care
- DTIL Health Care
- Exchange
- ACRV Nasdaq
- DTIL Nasdaq
- Market Cap
- ACRV 47.8M
- DTIL 55.3M
- IPO Year
- ACRV 2022
- DTIL 2019
- Fundamental
- Price
- ACRV $1.56
- DTIL $4.53
- Analyst Decision
- ACRV Buy
- DTIL Strong Buy
- Analyst Count
- ACRV 6
- DTIL 2
- Target Price
- ACRV $17.75
- DTIL $47.00
- AVG Volume (30 Days)
- ACRV 3.5M
- DTIL 74.9K
- Earning Date
- ACRV 11-12-2025
- DTIL 11-03-2025
- Dividend Yield
- ACRV N/A
- DTIL N/A
- EPS Growth
- ACRV N/A
- DTIL N/A
- EPS
- ACRV N/A
- DTIL N/A
- Revenue
- ACRV N/A
- DTIL $1,261,000.00
- Revenue This Year
- ACRV N/A
- DTIL N/A
- Revenue Next Year
- ACRV $805.34
- DTIL $135.19
- P/E Ratio
- ACRV N/A
- DTIL N/A
- Revenue Growth
- ACRV N/A
- DTIL N/A
- 52 Week Low
- ACRV $1.05
- DTIL $3.61
- 52 Week High
- ACRV $8.74
- DTIL $10.48
- Technical
- Relative Strength Index (RSI)
- ACRV 58.63
- DTIL 40.62
- Support Level
- ACRV $1.46
- DTIL $4.86
- Resistance Level
- ACRV $2.67
- DTIL $5.17
- Average True Range (ATR)
- ACRV 0.19
- DTIL 0.24
- MACD
- ACRV 0.01
- DTIL -0.06
- Stochastic Oscillator
- ACRV 18.98
- DTIL 4.48
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.